STOCK TITAN

Cellectar Biosciences (CLRB) grants COO 118,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cellectar Biosciences Chief Operating Officer Jarrod Longcor received a grant of stock options as equity compensation. The award covers 118,000 shares of common stock at an exercise price of $3.14 per share and expires on May 28, 2036.

The option was contingently granted on May 28, 2026 and became effective after stockholders approved the amended 2021 Stock Incentive Plan on July 7, 2026. It vests over three years, with one-third vesting on the first anniversary of May 28, 2026 and the remaining two-thirds vesting in 24 equal monthly installments thereafter.

Positive

  • None.

Negative

  • None.
Insider Longcor Jarrod
Role Chief Operating Officer
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 118,000 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 118,000 shares (Direct, null)
Footnotes (1)
  1. This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026
Option grant size 118,000 options Stock option grant to COO covering common stock
Exercise price $3.14 per share Strike price for the COO’s stock options
Expiration date May 28, 2036 Option term for the COO grant
Vesting period 3 years From May 28, 2026 with staged vesting
Initial cliff vesting 1/3 of options Vests on first anniversary of May 28, 2026
Monthly vesting installments 24 installments Remaining two-thirds vest over 24 months after first anniversary
Stock option financial
"This option was contingently granted on May 28, 2026, subject to approval"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "3.1400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option shall vest over a period of three years from May 28, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
amended 2021 Stock Incentive Plan financial
"subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan"
grant, award, or other acquisition financial
"transaction_code_description": "Grant, award, or other acquisition""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Cellectar Biosciences (CLRB) disclose about Jarrod Longcor in this Form 4?

Cellectar Biosciences reported that Chief Operating Officer Jarrod Longcor received a grant of stock options covering 118,000 shares of common stock. These options were issued as equity compensation and reflect a non-cash award linked to the company’s amended 2021 Stock Incentive Plan.

How many Cellectar (CLRB) stock options were granted to the COO and at what price?

The COO received 118,000 stock options, each with an exercise price of $3.14 per share. This price is the amount he must pay to purchase each share if he chooses to exercise the options in the future.

When do Jarrod Longcor’s Cellectar (CLRB) stock options vest?

The options vest over three years starting from May 28, 2026. One-third vests on the first anniversary of that date, and the remaining two-thirds vest in 24 equal monthly installments over the following two years.

What approvals were required for the Cellectar (CLRB) COO option grant?

The option grant was contingent on stockholder approval of Cellectar’s amended 2021 Stock Incentive Plan. Stockholders approved the plan at the 2026 Annual Meeting of Stockholders held on July 7, 2026, making the contingent grant effective.

What is the expiration date of the Cellectar (CLRB) stock options granted to the COO?

The stock options granted to the COO expire on May 28, 2036. After this date, any unexercised options will lapse, meaning they can no longer be used to purchase Cellectar Biosciences common stock at the $3.14 exercise price.

Is the Cellectar (CLRB) COO option grant an open-market purchase or a compensation award?

The Form 4 describes the transaction as a grant or award acquisition, not an open-market purchase. This means the options were issued as part of his compensation package rather than bought on the open market for cash.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Longcor Jarrod

(Last)(First)(Middle)
C/O CELLECTAR BIOSCIENCES, INC.
100 CAMPUS DRIVE

(Street)
FLORHAM PARK NEW JERSEY 07932

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)$3.1407/07/2026(1)A118,000 (2)05/28/2036Common stock118,000$0118,000D
Explanation of Responses:
1. This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.
2. This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026
/s/ Chad Kolean, attorney-in-fact for Jarrod D. Longcor07/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)